Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects

M. Artman, Mark D Parrish, R. C. Boerth, R. J. Boucek, T. P. Graham

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We evaluated the acute hemodynamic responses to hydralazine during cardiac catheterization in eight infants (ages 1.0 to 5.5 months) with congestive heart failure due to complete atrioventricular canal defect. Hydralazine administered intravenously (0.5 to 1.0 mg/kg body weight) increased heart rate and systemic blood flow and decreased mean right atrial pressure, systemic and pulmonic arterial pressures, systemic arteriolar resistance, and the ratio of pulmonary to systemic blood flow (p < .05). The percentage of pulmonary flow contributed by shunted blood (percent left-to-right shunt; measured by indicator dilution) was decreased by hydralazine in six (mean = 85% before to 64% after hydralazine; p < .01), but remained unchanged (79%) in two infants. The two infants with no change in percent left-to-right shunt had higher pulmonary arteriolar resistances (Rp) before hydralazine (mean = 12.8 vs 3.2 U/m2) and had greater declines in Rp (mean change = -5.1 vs +0.3 U/m2) in response to hydralazine. Thus, if Rp does not fall, hydralazine reduces the percentage of left-to-right shunt over the short term and therefore might be useful for managing congestive heart failure in these infants. However, because the response varies, an evaluation of the short-term hemodynamic effects of hydralazine may be warranted in an attempt to select those infants who might respond favorably to long-term hydralazine therapy.

Original languageEnglish (US)
Pages (from-to)949-954
Number of pages6
JournalCirculation
Volume69
Issue number5
StatePublished - 1984
Externally publishedYes

Fingerprint

Hydralazine
Hemodynamics
Lung
Heart Failure
Atrioventricular Septal Defect
Complete atrioventricular septal defect
Atrial Pressure
Cardiac Catheterization
Arterial Pressure
Heart Rate
Body Weight

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Artman, M., Parrish, M. D., Boerth, R. C., Boucek, R. J., & Graham, T. P. (1984). Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. Circulation, 69(5), 949-954.

Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. / Artman, M.; Parrish, Mark D; Boerth, R. C.; Boucek, R. J.; Graham, T. P.

In: Circulation, Vol. 69, No. 5, 1984, p. 949-954.

Research output: Contribution to journalArticle

Artman, M, Parrish, MD, Boerth, RC, Boucek, RJ & Graham, TP 1984, 'Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects', Circulation, vol. 69, no. 5, pp. 949-954.
Artman, M. ; Parrish, Mark D ; Boerth, R. C. ; Boucek, R. J. ; Graham, T. P. / Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. In: Circulation. 1984 ; Vol. 69, No. 5. pp. 949-954.
@article{62eb27bdfb534a8f9277bf61cab4c1d5,
title = "Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects",
abstract = "We evaluated the acute hemodynamic responses to hydralazine during cardiac catheterization in eight infants (ages 1.0 to 5.5 months) with congestive heart failure due to complete atrioventricular canal defect. Hydralazine administered intravenously (0.5 to 1.0 mg/kg body weight) increased heart rate and systemic blood flow and decreased mean right atrial pressure, systemic and pulmonic arterial pressures, systemic arteriolar resistance, and the ratio of pulmonary to systemic blood flow (p < .05). The percentage of pulmonary flow contributed by shunted blood (percent left-to-right shunt; measured by indicator dilution) was decreased by hydralazine in six (mean = 85{\%} before to 64{\%} after hydralazine; p < .01), but remained unchanged (79{\%}) in two infants. The two infants with no change in percent left-to-right shunt had higher pulmonary arteriolar resistances (Rp) before hydralazine (mean = 12.8 vs 3.2 U/m2) and had greater declines in Rp (mean change = -5.1 vs +0.3 U/m2) in response to hydralazine. Thus, if Rp does not fall, hydralazine reduces the percentage of left-to-right shunt over the short term and therefore might be useful for managing congestive heart failure in these infants. However, because the response varies, an evaluation of the short-term hemodynamic effects of hydralazine may be warranted in an attempt to select those infants who might respond favorably to long-term hydralazine therapy.",
author = "M. Artman and Parrish, {Mark D} and Boerth, {R. C.} and Boucek, {R. J.} and Graham, {T. P.}",
year = "1984",
language = "English (US)",
volume = "69",
pages = "949--954",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects

AU - Artman, M.

AU - Parrish, Mark D

AU - Boerth, R. C.

AU - Boucek, R. J.

AU - Graham, T. P.

PY - 1984

Y1 - 1984

N2 - We evaluated the acute hemodynamic responses to hydralazine during cardiac catheterization in eight infants (ages 1.0 to 5.5 months) with congestive heart failure due to complete atrioventricular canal defect. Hydralazine administered intravenously (0.5 to 1.0 mg/kg body weight) increased heart rate and systemic blood flow and decreased mean right atrial pressure, systemic and pulmonic arterial pressures, systemic arteriolar resistance, and the ratio of pulmonary to systemic blood flow (p < .05). The percentage of pulmonary flow contributed by shunted blood (percent left-to-right shunt; measured by indicator dilution) was decreased by hydralazine in six (mean = 85% before to 64% after hydralazine; p < .01), but remained unchanged (79%) in two infants. The two infants with no change in percent left-to-right shunt had higher pulmonary arteriolar resistances (Rp) before hydralazine (mean = 12.8 vs 3.2 U/m2) and had greater declines in Rp (mean change = -5.1 vs +0.3 U/m2) in response to hydralazine. Thus, if Rp does not fall, hydralazine reduces the percentage of left-to-right shunt over the short term and therefore might be useful for managing congestive heart failure in these infants. However, because the response varies, an evaluation of the short-term hemodynamic effects of hydralazine may be warranted in an attempt to select those infants who might respond favorably to long-term hydralazine therapy.

AB - We evaluated the acute hemodynamic responses to hydralazine during cardiac catheterization in eight infants (ages 1.0 to 5.5 months) with congestive heart failure due to complete atrioventricular canal defect. Hydralazine administered intravenously (0.5 to 1.0 mg/kg body weight) increased heart rate and systemic blood flow and decreased mean right atrial pressure, systemic and pulmonic arterial pressures, systemic arteriolar resistance, and the ratio of pulmonary to systemic blood flow (p < .05). The percentage of pulmonary flow contributed by shunted blood (percent left-to-right shunt; measured by indicator dilution) was decreased by hydralazine in six (mean = 85% before to 64% after hydralazine; p < .01), but remained unchanged (79%) in two infants. The two infants with no change in percent left-to-right shunt had higher pulmonary arteriolar resistances (Rp) before hydralazine (mean = 12.8 vs 3.2 U/m2) and had greater declines in Rp (mean change = -5.1 vs +0.3 U/m2) in response to hydralazine. Thus, if Rp does not fall, hydralazine reduces the percentage of left-to-right shunt over the short term and therefore might be useful for managing congestive heart failure in these infants. However, because the response varies, an evaluation of the short-term hemodynamic effects of hydralazine may be warranted in an attempt to select those infants who might respond favorably to long-term hydralazine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021246054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021246054&partnerID=8YFLogxK

M3 - Article

C2 - 6705171

AN - SCOPUS:0021246054

VL - 69

SP - 949

EP - 954

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -